2010
Analytic Variability in Immunohistochemistry Biomarker Studies
Anagnostou VK, Welsh AW, Giltnane JM, Siddiqui S, Liceaga C, Gustavson M, Syrigos KN, Reiter JL, Rimm DL. Analytic Variability in Immunohistochemistry Biomarker Studies. Cancer Epidemiology Biomarkers & Prevention 2010, 19: 982-991. PMID: 20332259, PMCID: PMC3891912, DOI: 10.1158/1055-9965.epi-10-0097.Peer-Reviewed Original ResearchConceptsHuman epidermal growth factor receptor 3Cancer patientsEstrogen receptorWestern blottingBiomarker studiesEpidermal growth factor receptor 1Breast cancer patientsLung cancer patientsEpidermal growth factor receptor 3Growth factor receptor 1Factor receptor 1Growth factor receptor 3Clone 1D5Worse prognosisHigher eGFRPrognostic classificationER antibodyCancer-related biomarkersCutoff pointBT474 cellsSurvival analysisEGFR antibodyReceptor 1Receptor 3Quantitative immunofluorescence
2007
EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN)
Kies M, Ghebremichael M, Katz T, Herbst R, Youssoufian H, Burtness B. EGFR expression by immunohistochemistry (IHC) and response to chemotherapy and cetuximab in squamous cell carcinoma of the head and neck (SCCHN). Journal Of Clinical Oncology 2007, 25: 6024-6024. DOI: 10.1200/jco.2007.25.18_suppl.6024.Peer-Reviewed Original ResearchHigh EGFR expressionEGFR expressionRecurrent SCCHNTumor samplesCisplatin-based chemotherapySquamous cell carcinomaAssociation of responsePercentage of cellsHazard ratioProgressive diseaseCisplatin therapyPatient selectionCell carcinomaHigher eGFREGFR immunoreactivityInitial cohortCetuximabChemotherapyIndependent cohortFurther enrollmentPatientsSurvival analysisTumor resistanceDako kitSCCHN
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply